The article you requested is
Academic Highlights: Recent Advances in the Treatment of Depression in the Presence of Physical Symptoms.[CME]
his Academic Highlights section of The Journal of Clinical Psychiatry presents the highlights from the teleconference "Recent Advances in the Treatment of Depression in the Presence of Physical Symptoms," which was held July 27, 2005. This report was prepared by the CME Institute of Physicians Postgraduate Press, Inc. and was supported by an educational grant from Eli Lilly and Company.
The planning teleconference was chaired by Madhukar H. Trivedi, M.D., Department of Psychiatry, University of Texas, Southwestern Medical Center at Dallas. The faculty were Wayne J. Katon, M.D., Department of Psychiatry, University of Washington, Seattle; Ella Daly, M.B., M.R.C.Psych., Department of Psychiatry, University of Texas, Southwestern Medical Center at Dallas; Anita H. Clayton, M.D., David C. Wilson Professor and Vice Chair, Medical Director, University of Virginia Center for Psychiatric Clinical Research, Charlottesville; and Ellen Frank, Ph.D., Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, Pa.
Faculty financial disclosure: In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this CME article were asked to complete a statement regarding all relevant financial relationships between themselves or their spouse/partner and any commercial interest (i.e., a proprietary entity producing health care goods or services) occurring within the 12 months prior to joining this activity. The CME Institute has resolved any conflicts of interest that were identified. The disclosures are as follows: Dr. Trivedi has received grant/research support from National Institute of Mental Health (NIMH), Abbott, Akzo (Organon), Bayer, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Johnson & Johnson, Mead Johnson, Parke-Davis, Pfizer, Pharmacia & Upjohn, Solvay, Wyeth, and National Alliance for Research on Schizophrenia and Depression (NARSAD) and is a consultant for or member of the speakers bureaus of Bristol-Myers Squibb, Cyberonics, Forest, Janssen, Eli Lilly, Organon, Pfizer, Pharmacia & Upjohn, Solvay, and Wyeth. Dr. Clayton is a consultant for Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKline, Pfizer, Vela, and Wyeth; has received grant/research support from Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Neuronetics, Pfizer, and Wyeth; has received honoraria from Eli Lilly, GlaxoSmithKline, Pfizer, and Wyeth; and is a member of the speakers/advisory boards of Bayer, Eli Lilly, GlaxoSmithKline, Pfizer, and Wyeth. Dr. Frank is a consultant for Eli Lilly, Pfizer, Pfizer Italia, and Servier and has received grant/research support from Forest, NIMH, and Pittsburgh Foundation. Dr. Katon is a consultant for Eli Lilly and GlaxoSmithKline and has received honoraria from and is a member of the speakers/advisory boards of Eli Lilly, Forest, GlaxoSmithKline, Wyeth, and Pfizer. Dr. Daly has no significant commercial relationships to disclose relative to the presentation.
The opinions expressed herein are those of the authors and do not necessarily reflect the views of the CME provider and publisher or the commercial supporter.